J&J’s acquisition of Guidant is uncertain due to the FDA’s scrutiny of Guidant’s recent quality problems. But Guidant hometown newspaper, the Indianapolis Star points out that J&J’s Cordis stent division has had quality problems and FDA scrutiny as well.
The Star sees the glass as being half full:
[T]he problems at Cordis give Johnson & Johnson a similar experience as it tries to better understand the issues involved in Indianapolis-based Guidant’s regulatory problems.
PS, I misspelled Guidant when I wrote this post. The Blogger spellchecker suggested â€œgoddamnedâ€ as a replacement.November 1, 2005